M&A / Deals Kailera makes history with record-breaking $625m IPO Pharmaceutical TechnologyKailera's IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials. M&A / DealsRead full story Post navigation Previous: Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery toolNext: Trump signs order to hasten psychedelic medicine access Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026